Compare ReWalk Robotics Ltd. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 13 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.16
-135.37%
1.00
Revenue and Profits:
Net Sales:
6 Million
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.93%
0%
-1.93%
6 Months
-22.46%
0%
-22.46%
1 Year
-59.19%
0%
-59.19%
2 Years
-91.98%
0%
-91.98%
3 Years
-35.73%
0%
-35.73%
4 Years
-93.26%
0%
-93.26%
5 Years
-97.68%
0%
-97.68%
ReWalk Robotics Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
38.23%
EBIT Growth (5y)
-9.46%
EBIT to Interest (avg)
-17.50
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
0.84
Tax Ratio
0.17%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
15.79%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.76
EV to EBIT
-0.48
EV to EBITDA
-0.58
EV to Capital Employed
0.66
EV to Sales
0.34
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-136.62%
ROE (Latest)
-95.94%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 2 Schemes (0.21%)
Foreign Institutions
Held by 10 Foreign Institutions (4.9%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
5.70
5.00
14.00%
Operating Profit (PBDIT) excl Other Income
-3.70
-4.80
22.92%
Interest
0.00
0.00
Exceptional Items
-2.80
0.00
Consolidate Net Profit
-6.60
-4.80
-37.50%
Operating Profit Margin (Excl OI)
-660.40%
-964.00%
30.36%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 14.00% vs -33.33% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -37.50% vs 68.63% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
25.70
13.90
84.89%
Operating Profit (PBDIT) excl Other Income
-15.70
-18.60
15.59%
Interest
0.10
0.00
Exceptional Items
-9.80
-3.20
-206.25%
Consolidate Net Profit
-28.90
-22.10
-30.77%
Operating Profit Margin (Excl OI)
-761.90%
-1,475.50%
71.36%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 84.89% vs 152.73% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -30.77% vs -12.76% in Dec 2023
About ReWalk Robotics Ltd. 
ReWalk Robotics Ltd.
Pharmaceuticals & Biotechnology
ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers two ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides exercise and therapy.
Company Coordinates 
Company Details
3 Hatnufa st. 6th fl.,, P.O. Box 161 YOKNEAM None : 2069203
Registrar Details






